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ABSTRACT
Background The PROTECT Beneﬁt–Risk group is dedicated to research in methods for continuous beneﬁt–risk monitoring of medicines,
including the presentation of the results, with a particular emphasis on graphical methods.1Q4
Methods A comprehensive review was performed to identify visuals used for medical risk and beneﬁt–risk communication. The identiﬁed
visual displays were grouped into visual types, and each visual type was appraised based on ﬁve criteria: intended audience, intended mes-
sage, knowledge required to understand the visual, unintentional messages that may be derived from the visual and missing information that
may be needed to understand the visual.
Results Sixty-six examples of visual formats were identiﬁed from the literature and classiﬁed into 14 visual types. We found that there is
not one single visual format that is consistently superior to others for the communication of beneﬁt–risk information. In addition, we found
that most of the drawbacks found in the visual formats could be considered general to visual communication, although some appear more
relevant to speciﬁc formats and should be considered when creating visuals for different audiences depending on the exact message to be
communicated.
Conclusion We have arrived at recommendations for the use of visual displays for beneﬁt–risk communication. The recommendation re-
fers to the creation of visuals. We outline four criteria to determine audience–visual compatibility and consider these to be a key task in cre-
ating any visual. Next we propose speciﬁc visual formats of interest, to be explored further for their ability to address nine different types of
beneﬁt–risk analysis information. Copyright © 2015 John Wiley & Sons, Ltd.
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BACKGROUND
This review was carried out as part the Innovative Med-
icine Initiative Pharmacoepidemiological Research on
Outcomes of Therapeutics by a European Consortium
(PROTECT) project work package 5 beneﬁt–risk inte-
gration and representation (PROTECT BR group). PRO-
TECT BR group is dedicated to research in methods for
continuous beneﬁt–risk (BR) monitoring of medicines,
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†The contents of this paper have previously been presented at various scientiﬁc
conferences, and a preliminary full report of this review has also been published
online on the project website http://www.imi-protect.eu/.
Copyright © 2015 John Wiley & Sons, Ltd.
pharmacoepidemiology and drug safety 2015
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3880
Journal Code Article ID Dispatch: 13.09.15 CE: Jan April Same
P D S 3 8 8 0 No. of Pages: 13 ME:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
including both the underpinning modelling and the pre-
sentation of the results, with a particular emphasis on
graphical methods.1 This literature review of visual rep-
resentation and visual/graphical formats for BR commu-
nication followed a review of methods for medicinal BR
assessment2; both were used to provide input to the
PROTECT BR group case studies exploring the utility
of BR methods and visual formats for communication
in connection with BR assessment.
When communicating about BR, it is important to
be aware that we distinguish between efﬁcacy and
safety data on the one hand and beneﬁt and risk on
the other, requiring interpretation of the efﬁcacy and
safety data for their clinical and therapeutic relevance.
Beneﬁts are deﬁned as favourable effects and risks as
unfavourable effects, separate from the uncertainty of
experiencing the effects.3
Visual representation of BR information for
decision-making of medicinal products is not
completely exclusive to PROTECT BR group. We
gained insight from other resources as a starting point
for this review, including the recent BR Methodology
Project commissioned by the European Medicines
Agency (EMA) and the US Food and Drug Adminis-
tration commissioned study to investigate the value
of adding quantitative summaries of beneﬁts and risks
in standardised formats including visual displays and
numerical formats.4 More general initiatives on visual
representation of data and communication by special
interest groups and individuals are available on the In-
ternet.5–14
The aim of this review is to evaluate the usefulness
of different visual types for the representation and
communication of BR assessment information.
METHOD
Literature search strategy
We conducted a comprehensive review of the litera-
ture and searched for articles on BR communication
and visual formats for risk communication, published
after the year 2000 on Scopus up until February
2014, PubMed, Web of Science and PsycINFO (for
details of search terms, see Supporting Information).Q5
The reference list of articles that met our inclusion
criteria was screened for relevant publications. In addi-
tion, we included related materials that were known to
us at the time from the PROTECT BR group case stud-
ies, other initiatives, scientiﬁc conferences and
websites on the Internet.
One reviewer (C.E.H.) examined titles and ab-
stracts of identiﬁed articles. Relevant articles were
obtained in full and assessed against the inclusion
criteria described in the following.
Furthermore, we identiﬁed visual formats linked to
BR assessment methodologies from a recent review2
and highlight prominent visual formats associated with
each method.
Inclusion criteria and data extraction
First screening included articles if title or abstract re-
ferred to communication, presenting information on
risk, efﬁcacy or safety data or BR and/or graphical
representation/information. In the following, full text
screening articles were included that present or discuss
one or more visual formats to communicate beneﬁt or
risk information or information in connection to BR as-
sessment. From each relevant article, examples of the
visual formats presented or discussed were extracted
and also any relevant discussion and comment on the
strengths and weaknesses of the visual format.
Appraisal criteria and strategy
The authors C.E.H., S.M. and A.L. identiﬁed distinct
visual formats from the literature and grouped them
into visual types, such as, but not limited to, bar charts,
pie charts or line graphs. The visual types were ap-
praised at group level initially. We made some com-
ments on special cases or variation of the visual types
where necessary.
The authors C.E.H., S.M. and A.L. appraised each
group of visual type against ﬁve criteria: intended audi-
ence, intended message, knowledge required to under-
stand the visuals, unintentional message that may be
associated with the visuals and any missing informa-
tion from the visuals that may be needed to understand
them (for appraisal criteria description, see Table 7 or
Supporting Information). We then consolidated that
appraisals discussed and resolved any conﬂicts with
the study team through emails, teleconferences and a ﬁ-
nal face-to-face meeting.
Because we were not able to formally test individ-
ual’s comprehension, we approached the appraisal
process theoretically based on two sets of principles
for visual display design: Wickens’ principles of dis-
play design15 and Cleveland’s elementary perceptual
tasks.16,17
We framed our recommendation of visual formats to
be used in medical BR communication and representa-
tion through nine key BR questions. The key BR ques-
tions were adapted from the work of the Communities
and Local Government (CLG) on visual representation
c. e. hallgreen et al.2
Copyright © 2015 John Wiley & Sons, Ltd. Pharmacoepidemiology and Drug Safety, 2015
DOI: 10.1002/pds
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
of data in the public sector, as appeared on the CLG
DataViz website.7
RESULTS
Searches identiﬁed 4855 potentially relevant articles
from the scientiﬁc literature. Following title and ab-
stract screening, more than 500 were examined in full
text and of those, 55 were deemed eligible.16,18–71
Q6 Fourteen additional sources for visuals were identiﬁed
including websites and reports.4,7–14,72–76 From the 55
identiﬁed articles and the 14 additional sources, we ex-
tracted 66 examples of visual formats (for details of
search, see Supporting Information). In addition, we
extracted additional 33 examples of visual formats as-
sociated directly with BR methodologies identiﬁed in
a separate literature review of BR methodologies.2 In
Table T11, the visual types that are connected to speciﬁc
BR assessment methodologies are presented.
The extracted visual formats were classiﬁed into 13
visual types, of which several include sub-groups of
the variations with speciﬁc properties and ways of pre-
sentation (Table T22). The classiﬁcations were based on
the well-accepted terminologies of the visual formats
from our past experience.
In Table T33, we present a selection of visual formats
that have more speciﬁc use in data representation and
therefore may be more unfamiliar to lay readers. This
is to give an idea of how an unfamiliar visual format
might look. The examples in Table 3 include specialist
visual formats aimed at general audiences, such as a
value tree, a risk scale and a pictogram. These also in-
clude three variations of bar charts communicating
speciﬁc information in speciﬁc structures (waterfall
plot, difference display and tornado diagram) and vi-
sual formats that communicate statistical information
Table 1. Overview of visual representation connected to beneﬁt–risk
methodologies
Approach
Visual
representation of
results
Other visual representations of special
interest
PrOACT-
URL
‘Effects’ table N/A
PhRMA
BRAT
Table, dot/forest
plot, bar graph
Tree diagram to represent model.
MCDA Bar graph,
‘difference display’
Table for evidence data, tree diagram
to represent model, line graph for
sensitivity analysis.
SMAA Bar graph, dot/
forest plot
Table for evidence data, tree diagram
and distribution plot to represent
model, line graph and scatter plot for
sensitivity analysis.
BRR Bar graph, dot/
forest plot, line
graph
Scatter plot or contour plot for
sensitivity analysis. Tornado diagram
may be suitable to simplify further the
results.
NNT/
NNH
Dot/forest plot, line
graph, scatter plot
Contour plot for sensitivity analysis.
Tornado diagram may be suitable to
simplify further the results.
INHB Line graph, scatter
plot
Contour plot for sensitivity analysis.
Impact
numbers
Dot/forest plot, line
graph, scatter plot
Contour plot for sensitivity analysis.
Tornado diagram may be suitable to
simplify further the results.
QALY Bar graph, dot/
forest plot
Line graph or scatter plot for
sensitivity analysis.
Q-
TWiST
Bar graph, dot/
forest plot
Line graph or scatter plot for
sensitivity analysis.
PSM N/A Network graph to represent model.
MTC N/A Network graph to represent model.
DCE Bar graph Line graph or scatter plot for
sensitivity analysis.
PrOACT-URL, problem, objective, alternative, consequence, trade-off, un-
certainty, risk tolerance, linked decisions; PhRMA BRAT, Pharmaceutical
Research and Manufacturers of America Beneﬁt–Risk Action Team;
MCDA, multi-criteria decision analysis; SMAA, stochastic multi-criteria
acceptability analysis; BRR, beneﬁt–risk ratio; INHB, incremental net
health beneﬁt; NNT/NNH, numbers needed to treat/numbers needed to
harm; QALY, quality-adjusted life years; Q-TWiST, quality-adjusted time
without symptoms and toxicity; PSM, probabilistic simulation method;
MTC, mixed treatment comparison; DCE, discrete choice experiment.
Table 2. Visual types and visual type sub-groups
Visual type Sub-group Reference
Area graphs Area graph 16,23,38,46,58,67,76
Distributions plots 14,67
Volume graphs 46,67
Frontier graph 53
Bar chart Simple bar chart 16,22,23,29,35,40,46,49,50,59,62,67
Grouped bar chart 16,24,32,40,46,50,54,59,64,66,67,69
Divided/stacked
bar chart
16,23,25,28–
30,33,37,39,46,47,54,67–71,73
Difference
diagram
72
Tornado diagram
Waterfall plots
Box plot 28,34,46,50,56,67
Cartoons, symbols
and icons
21,46,50,52,55,64,67,74,77
Dot chart Dot chart 16,28,40,46,67
Forest plot 20,68,73,78
Line graphs Line graph 16,22–24,28,35,46,50,54,60,66,67
Frontier area
graph
17
Maps Statistical maps 16,22,31,67
Sector maps
(tree map)
Pictograms 18,22,23,25,30–33,35,36,40–42,44,47,
50,52,54,57,59,60,65,67,70,71,77
Pie charts Pie charts 16,22,23,28,35,40,46,50,63,67,71
Nightingale rose 50
Speedometer 52
Risk scales/ladder 18,22,26,32,45,48,49,61,64,65
Scatter plot 16,28,46,66,67
Tables 23,30,38,40,46,65,67
Tree diagram Tree diagram 30,38,47
Value tree 78
Q1
visuals for beneﬁt–risk representation 3
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such as the box plot and forest plot. A dot plot is also
shown, which is a part of a forest plot (middle part to
show the values of any point estimates). The forest
plot is sometimes referred to as a ‘range’ graph.
To facilitate the recommendations from this review,
we adapted the CLG DataViz’s common questions on
visual data representation in the public sector to the
BR scenario.7 The nine adapted BR questions are
shown in TableT4 4.
We found that several visual formats could be used
in each of the pre-speciﬁed BR questions, depending
on the exact message to be communicated and to
whom different visuals could be relevant. Table T55
gives an overview of which visual formats have the
potential to be used in connection to the common BR
questions. This is shown together with the information
of level of expertise that is considered to be required to
interpret the visual format and how the visual formats
Table 3. Examples of selected visual formats,† from the top left, the value tree, the risk scale, a pictogram, a waterfall plot, a difference display, a tornado
diagram, a box plot, a dot plot and in the bottom right corner a forest plot
Note: For example, the criteria could be favourable clinical events such as improvement in cholesterol levels or reduced disease progression, and/or
unfavourable outcomes such as increased risk of diarrhoea, psychiatric disorders or cardiovascular disorders. Alternatives A and B on these visuals may refer
to alternative treatments such as rimonabant and placebo for weight loss.Q7
†For more examples, see Supporting Information or www.imi-protect.eu/beneﬁt-risk.
c. e. hallgreen et al.4
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are ranked according to Cleveland’s elementary per-
ceptual tasks.16 For a more in-depth description of
the appraisal of each visual type, see Supporting
Information or the PROTECT BR review of visual for-
mats for the representation of BR assessment of med-
ication Stage 2.79
Table 4. Adaptation of CLG DataViz’s data exploration question to BR questions (non-chronological), the CLG question is presented in the left column and
our adaptation to BR assessment in the right. The ﬁrst CLG question was speciﬁed into two BR questions
CLG questions Adaptation to BR assessment
Example (possible question to visually representing BR
results of a weight loss drug)
How to compare data? 1. How do I represent the (raw) magnitudes of quantitative
data such as the probabilities of events to describe data
and to put them into context?
How do I represent the percentages of people who achieved a
10% weight loss and experienced diarrhoea for those taking
rimonabant versus placebo?
2. How do I represent the magnitude of the ﬁnal BR metrics
to allow easy comparison of the BR balance to be made?
How do I represent the overall BR score to easily compare
rimonabant and placebo for weight loss?
What is changing over time? 3. How do I represent how the magnitude of a measure is
changing against a range of another measure such as time
or a range of preference values?
How do I represent the relationship between the score for
weight loss and preference weight?
What is the distribution
of an indicator variable?
4. How do I visualise the distributions or uncertainty of
safety and efﬁcacy data, preferences or a BR metric?
How do I represent the viability of data for weight loss
observed in different trials?
What are the components
of an indicator variable?
5. How do I represent the contributions from the different
criteria (components) in a BR analysis to allow better
perception of the key drivers?
How do I show visually which of the adverse events in the
BR analysis contributes most (or least) to the overall BR
score?
What is the relationship
between indicator variables?
6. How do I represent the strength of the relationships
between beneﬁt and risk metrics, for example, to visualise
many data points such as patient-level data or to visualise
the extent of correlation between criteria?
How do I represent the relationship between people who
achieved 10% weight loss and those who experienced
diarrhoea, to visually explore whether diarrhoea and weigh
loss occur together?
How signiﬁcant are the
differences?
7. How do I represent the degree of statistical signiﬁcance in
the difference between alternatives?
How do I represent to which extent rimonabant is a more
preferred option compared to placebo, given the current
evidence and assumptions?
How to visualise qualitative
data?
8. How do I represent and present qualitative data such as
text descriptions meaningfully and simply to support
judgement without introducing extra cognitive burden?
How do I represent the rates of depression and diarrhoea
associated with rimonabant and placebo to indicate that
diarrhoea may be a more unfavourable side effect?
How to visualise categorical
data?
9. How do I represent categorical data such as groups of
patients, discrete events and categorical value function
without distorting the data they are presenting?
How do I represent the percentages of people by the level of
improvement in HDL cholesterol, for example, ‘improved’,
‘did not change’, ‘got worse’?
CLG, Communities and Local Government; BR, beneﬁt–risk; HDL, high-density lipoprotein.
Table 5. Information on the level of expertise required for interpreting visual types, the rank of visuals according to Cleveland’s elementary perceptual tasks
and the visual types’ ability to communicate \messages connected to the central beneﬁt–risk (BR) questions, as indicated by an ‘x’
Cartoons
Network
maps Pictogram Table
Tree
diagram
Simple
bar chart
Grouped
bar chart
Dot
chart
Line
graph
Level of expertise required E E E E E E E E E
Rank at elementary perceptual task (1–7) — — — — — 1 1 1 1
Represent magnitudes of measures and
ease comparison
x x x x x x
Represent change in a magnitude of a
measure over the range of another measure
x x
Represent the distribution or uncertainty
of a measure
Represent contributions from different
criteria to BR
x
Represent the strength of relationships
between measures
Represent degree of statistical
signiﬁcance
Represent qualitative data x x x x x
Represent categorical data x x x
E (easy)—no or very little expertise is required of the users to understand the visuals presented. Q8It is accessible to patients, general public and suitable for mass
media communicationQ9 . The visual may be presented to user without much explanation.
M (intermediate)—some experience with straightforward BR assessment methodology may be required of the users in is not necessary to understand the the-
oretical foundation of the model. Q10It is accessible to practicing physicians and patients’ representatives who need to understand and communicate BR to patients,
caregivers or general public. The visuals may be presented to users without much explanation but would beneﬁt from annotations or experts’ explanation.
D (difﬁcult)—some experience and familiarity with complex BR assessment methodology, decision analysis and statistics may be required to fully exploit and
understand these visuals. It is accessible to BR experts in regulatory agencies, pharmaceutical companies and academia and is suitable for specialist publication
only for making high-level decisions Q11. The visuals may also beneﬁt from clear annotations and labelling to avoid presenting misleading information.
visuals for beneﬁt–risk representation 5
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Effective visual representations of BR information
are not only limited to pictorial representations but
also include other components of the visual represen-
tation. This may result in the inclusion of words that
are prone to misinterpretation or misleading. There
is also a risk of potentially presenting insufﬁcient in-
formation. TableT6 6 gives an overview of some issues
to be considered with visual representation of BR as-
sessments. We also hypothesised (but have not tested)
that certain visual types may easily be associated with
the speciﬁc issues, based on the visual display exam-
ples extracted from the literature.
DISCUSSION
This review set out to appraise different visual types
for the representation and communication of BR
assessment information. We demonstrate that none of
the visual types can be used for all purposes (Table 5),
which concurs with the existing ﬁnding that there is
not one single visual type that is consistently superior
to others for the communication of BR information to
various stakeholders.4 This is partly due to the differ-
ent types of information to be presented and also partly
due to the differences in an individual’s perception,
understanding and preference of visuals.
Firstly, we want to point out the importance of con-
sidering the intended audience for the visual communi-
cation. Some visuals such as the simpler bar charts may
be used for a variety of groups from general public to
trained experts, whilst others like the pictogram or the
waterfall plot may have more targeted users. As for
the intended audience, the intended message is a main
factor in creating visuals. Although different messages
Table 5. (Continued)
Risk
ladder/risk
scale
Area
graph
Pie
chart Speedometer
Box
plot
Difference
display
Forest
plot
Scatter
plot
Statistical
map
Level of expertise required E E E E M M M M M
Rank at elementary perceptual task (1–7) 1 5 6 6 1 1 1 2 2
Represent magnitudes of measures and
ease comparison
x x x x x x x x
Represent change in a magnitude of a
measure over the range of another measure
x x
Represent the distribution or uncertainty
of a measure
x x x
Represent contributions from different
criteria to BR
x
Represent the strength of relationships
between measures
x
Represent degree of statistical
signiﬁcance
x x
Represent qualitative data
Represent categorical data x x x
Table 5. (Continued)
Stacked
bar chart
Distribution
plot
Waterfall
plot
Tornado
diagram
Frontier
graph
Sector
map
Level of expertise required M M D D D D
Rank at elementary perceptual task (1–7) 3 5 3 3 3 5
Represent magnitudes of measures and
ease comparison
x x x
Represent change in a magnitude of a
measure over the range of another measure
x x x
Represent the distribution or uncertainty
of a measure
x x x
Represent contributions from different
criteria to BR
x x
Represent the strength of relationships
between measures
x
Represent degree of statistical
signiﬁcance
x
Represent qualitative data
Represent categorical data x x
c. e. hallgreen et al.6
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can be communicated by a variety of visual types, the
level of detail that needs to be communicated can inﬂu-
ence the choice of visual type, for example, the stacked
bar chart can be used to communicate how each of the
criteria contribute to the overall BR balance, but if the
contributions from several criteria are similar, it can
be difﬁcult to discriminate their individual contribu-
tions; a grouped bar chart might be a better choice.
Whether the chosen visual representation causes an un-
intended message, or gives an unjust impression of cer-
tainty to the presented BR balance, should also be
considered. Furthermore, one should consider what
knowledge is required to interpret the visual, and this
is often related to technical skills such as understanding
the logarithmic scale or medical terms. In addition, it is
also important to ensure that the visual includes all nec-
essary information to correctly interpret and under-
stand the visual. This could be as simple as making
sure that the axes have the right labelling, or more
extensively as verbally describing/explaining the vi-
sual to the users to enhance the important information.
Table T77 outlines four criteria for determining audience–
visual compatibility.
In addition to determining audience–visual compat-
ibility when creating visuals for communication in BR
assessment, we recommend applying Wickens’ princi-
ples of display design15 and the GlaxoSmithKline
graphics principles.80 Although these principles were
not developed speciﬁcally for the visual representation
of BR assessments in medicine, they do offer some ad-
vice on the design of general visual representation,
which are easily adaptable for our purpose.
Despite our focus on static visual representations,
the principles can also be applied to interactive/
dynamic visual representation. We acknowledge that
interactive/dynamic visuals may be of great value be-
cause they enable active participation of the audience
that can increase attention and perception. Through
increasing,81 their use to display analysis results are
still uncommon and are not substitutes for poorly
designed static version of the visual display; the use
and choice of colours may also effect perception
Table 6. Overview of potential risk of misinterpretation related to visual communication
Issue Description
Examples of visual types related to
the issue
Verbal labels
Gradable adjectives Adjectives are easy and natural to be used in the presentation of BR assessment and may
better capture a person’s emotions and intuitions25,49 and can have the ability to put a
treatment into context. Examples of gradable adjectives are ‘high risk’ and ‘very high risk’.
Risk scales
Risk of misinterpretation is especially high if verbal labels are not accompanied by numerical
representation.60
Technical terms This could be medical or statistical terms that are not understood by an untrained audience.
Examples of technical terms are conﬁdence intervals, densities, utilities and cardiovascular
events.
Any visual type
Numerical
representation
It is important to be consistent in the use of numerical format when making comparison.49 Any visual type
There is a general consensus that relative frequencies are superior to percentages or
probabilities for a transparent communication of risk information.25,33,38,49
Relative risk (RR) A relative risk is a ratio of two incidence rates. RR may lead people to systematically
underestimate or overestimate treatment effects, depending on the effect size.26,33,38
Forest plot
RR does not, on its own, provide all the necessary information to the audience because it is
relative to a measurement that might be unknown to the audience.38
Denominator
neglect
An example of denominator neglect is the arbitrary and inconsistent use of denominators
when describing frequencies in different situations. For example, a frequency of an
unfavourable effect of 1 in 5 (1:5) may be perceived as safer than a frequency of an
unfavourable effect of 20 in a 100 (20:100), although they are exactly the same.25,50,54,60
Pictograms
Numerical representation as
frequencies
Logarithmic scales When visuals presenting logarithmic scales are not clearly labelled, they can cause users to
perceive consecutive risks as being additive rather than multiplicative, for example, reducing
a probability with 1 in 10 to 1 in 100 may be perceived as being the same as reducing a
probability with 1 in 100 to 1 in 1000.
Risk scales30 (which are often used
for an untrained audience Q12)
Forest plot showing relative risks or
odds ratios
Missing part-to-
whole information
Emphasises the foreground information without sufﬁcient background could lead to a
misperception of the difference in the measures such as the probabilities between two
events.18
Bar charts
Pictograms
Dot charts
Area/volume graphs
Abundance of
events
A long list of risks for a drug in comparison with short list of beneﬁts, for example, may be
perceived as an unfavourable beneﬁt–risk balance without taking into account the actual
quantitative data.
Tables
Tree diagrams
The right column states which visual formats are speciﬁcally related to a problem; this, however, does not mean that the problem should not be considered in
connection with other visual formats.
visuals for beneﬁt–risk representation 7
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and/or comprehension.79 We did not explore colours
in greater detail but recommend that users refer
to other research on colours when developing their
visual representations, for example, Color Brewer
(http://colorbrewer2.org) and J’FLY (http://jﬂy.iam.
u-tokyo.ac.jp/color).
We set out to propose visual types that could be of
interest when presenting information related to nine
central BR questions (Table 4). Here, particularly
Cleveland’s elementary perceptual tasks have been
our focus.16,17
A table can serve as a useful BR communication
tool because of its simple structure, ﬂexibility and
the ease with which it can be adapted. Readability
can be enhanced through the use of colour coding to
represent grouping and relationships, as carried out
in the Beneﬁt–Risk Action Team (BRAT) frame-
work.82 For tables, it is important to be aware that they
can be thought of as containing a list, with a long list
of risks perceived as having unfavourable BR balance
without taking into account the actual quantitative data
of their severity and incidence. The table is suitable for
many audiences from general public to experts. It
communicates well the criteria considered in a BR as-
sessment, their hierarchical structure and the statistical
summaries associated with the favourable and
unfavourable effects. The two main examples are the
key BR table from BRAT82 and the effect table from
PrOACT-URL.72
Tree diagrams can communicate qualitative infor-
mation, such as which beneﬁts and risks are pivotal
to the BR balance, and can represent the hierarchy of
associations among the criteria, as seen with the
BRAT.82 Like the table, it is important to be aware
of the potential downside that an imbalance in the
number of beneﬁt and risk criteria can be perceived
as an unbalanced BR proﬁle without taking into ac-
count the actual quantitative data.
The risk ladder/scale can facilitate comparison and
judgement; it often provides information on other risks
for comparison to particularly assist the general public
and patients as well as regulators in perceiving the
magnitude of risks under discussion.50 For the risk
scale, it is important to make sure that, if used, a loga-
rithmic scale is clearly marked and understood by the
audience. Risk ladders or scales are designed to ease
the communication of risks by anchoring the risks
against commonly understood scenarios; however, it
is important to make sure the anchors are understood
and relevant to the audience.
The pictogram has generally proven to be quickly
and better comprehended than other graphical formats
when used to communicating individual statis-
tics35,40,65 and can help to prevent patients from being
biased by other factors.33 Therefore, the pictogram is
of interest as an easily comprehended visual format
when communicating to the general public about the
relative frequencies of favourable effects and the inci-
dence of unfavourable effects.
The bar chart includes several special cases, where
the simple bar chart, stacked/divided bar chart and
grouped bar chart are the most familiar, the bar chart
is usually easy to read and interpret. For the stacked
bar chart, one should be aware that it can be more dif-
ﬁcult to rank order the categories than for the grouped
bar chart. Bar charts often best represent categorical
data; they only have one value axis, whilst the other
axis represents discrete categories such as groups.
The simpler bar charts (simple bar chart, Q13stacked bar
chart and the grouped bar chart) could be suitable
Table 7. Criteria to determine audience–visual compatibility prior to generating visuals
1. Intended audience. Specify the intended main audience/user and verify whether the ﬁnal visual is still suitable for the initially intended group
of audience.
•The main user(s) of the visual could be the general public/media, patient, prescriber, regulator or expert (medical, statistical and decision analyst).
If the visual is intended for more than one group of users, consider criteria 2–4 in the following for each group.
2. Message. Specify the main message of the visual and verify that the ﬁnal visual still communicates the intended message clearly and that it is
free from unintentionally misleading or confusing information.
•The main intended message could be information about the BR balance, input data, probability of an event, uncertainty related to input data or BR,
sensitivity of the beneﬁt risk analysis, integrated BR balance, the BR process and so on.
•Unintentional misleading/confusing message could be due to the visual display design itself, or the lack of user’s knowledge that was not anticipated
in the design stage. Unintentional messages could be incoherent reﬂection of the original data, any misleading assurance of the BR balance, the amount
of certainty/uncertainty of the BR balance are not presented sufﬁciently and so on.
3. Knowledge required. Specify the expected level of knowledge required to understand and to extract information from the visual. Verify that the ﬁnal
visual is at an appropriate level for the intended group of audience.
•Knowledge requirement could be any technical skills (e.g. understanding of logarithmic scale and concepts used in descriptive statistics), any medical
knowledge (e.g. severity of condition, reversible effects/events, passing events and conditional relationships) and any background information about
the measures in the visual (e.g. population affected). Ensure that the required knowledge is easily accessible by the users.
4. Message not communicated. For all of the aforementioned, verify in the ﬁnal visual that there are sufﬁcient representations of the information for
the intended message to be communicated and understood clearly.
BR, beneﬁt–risk.
c. e. hallgreen et al.8
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for a large variety of audiences such as the general
public through the media, patients, physicians, regula-
tors and other experts for communication about the ﬁ-
nal BR metric to visualise the contributions of the
different criteria (components) in the BR analysis
and categorical data. Special cases of the bar chart in-
clude the tornado diagram, the difference display and
the waterfall diagram (Table 3). The special cases
have many of the same features as the simpler bar
charts but will generally require more explanation to
be clearly understood. The difference display is rele-
vant to represent, for a trained audience, the contribu-
tions of the different criteria in the BR analysis and
was also recommended as a visual for displaying re-
sults of BR analysis in the recent report from EMA
BR Methodology Project.72 Q14The tornado diagram is
proposed for the communication of uncertainty of
the BR metric and visualisation of the relationships
between beneﬁt and risk metrics and correlated
criteria, again for a trained audience. Finally, the wa-
terfall plot can be used to communicate about the
level of contribution each beneﬁt and each risk pro-
vides to the overall BR balance.
The dot plot has similar features compared with the
simple bar chart and offers a very high data–ink ra-
tio.67 The forest plot is a special case of dot plot,
which contains more statistical underpinnings, and
can be used to represent summary measures such as
mean risk difference and risk ratios as well as their as-
sociated uncertainty via conﬁdence intervals, as in
BRAT,82 and is most suitable to a specialist audience
such as statisticians, physicians, regulators and other
experts.
Line graphs communicate the relationship of
changes in one measure such as frequency or probabil-
ity of an event over a range of values in another effect
—time, dose levels and so on. A line graph is a very
common type of visual display many people come
across in various media such as in the newspaper or
on television (e.g. stock values line graph and trends
in historical weather or the forecast). Although general
awareness may not be the best measure of broad appli-
cability of visual understanding in BR assessment,
such exposure to line graphs may make them suitable
for communication to most people.
Scatter plots allow users to perceive the strength of
relationship between any two uncertain quantities and
can also reﬂect the variability in the data. Scatter plots
are fairly intuitive and do not need any specialised
knowledge in order to understand them.
Box plots (also known as the box and whiskers dia-
gram) are used to convey statistical information by
presenting a summary of the dataset in terms of theirTa
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position in the data. The box plot can be used to repre-
sent the distributions of uncertainty for efﬁcacy and
safety data. Because of the technical constructions of
box plot, they may be limited to experts or trained au-
dience who have some understanding on statistical
summary measures such as medians, means, quartiles
and outliers.
The area graphs and volume charts suffer from peo-
ple’s ability to perceive area and volume differently.16
In the case of volume chart, it becomes worse because
of our limitation to accurately judge the size of three-
dimensional objects. The only area graph we ﬁnd of in-
terest is the distribution plot, which may look like a line
graph, but the information is actually being communi-
cated by the area under the curve. The distribution plot
is a well-known way of representing data distributions
for experts or a trained audience who have some under-
standing on statistics.Q15 It can be used to represent the
distribution or uncertainty of a measure, showing the
patient-level distribution of data, and to communicate
about the statistical signiﬁcance in the difference be-
tween alternatives to an expert audience.
Cartoons/icons or pictograms can be used to indi-
cate if something is a positive or a negative outcome,
inform about speciﬁc patient groups (e.g. men or
women) and indicate the direction of a change. Picto-
grams or cartoons have the potential to cross the
language barrier and would be particularly useful for
people who are sighted or partially sighted but are
unable to read. It is important that pictograms, car-
toons, icons or symbols used in BR visual representa-
tions are recognisable images that the intended users
would have had experience seeing in the past to sup-
port their understanding.15 Cultural differences may
be the most prohibitive when it comes to cartoons,
icons and symbols because the images may not be
common or could even be offending to some cultures.
The pie chart is an often a widely used visual; how-
ever, the reading of angles means that it scores fairly
low on Cleveland’s elementary perceptual task scale,
and it is difﬁcult to rank order categories and compare
between pie charts.16
Statistical maps in the form of geographical maps
may not be very relevant for use in the BR assessment.
A different type of statistical map is the ‘sector map’;
it is used as a type of graphical method to detect and
display differences in adverse event rates between
treatment groups. The sector map provides a high-
level overview of the situation and makes use of col-
our to encode information that can then be drilled
down to the required level of details. However, this
type of representation may be affected by the limita-
tions of area judgement and colour intensity.
CONCLUSIONS
Our main recommendation for the creation of visuals
for BR assessments is to determine the compatibility
between a visual and its target audience. This is carried
out by considering the intended audience for the visual,
the main message the visual should communicate and
the knowledge required to understand and to extract in-
formation from the visual. We speciﬁcally suggest
evaluating whether any message may be missed or
any unintended message could be drawn from a visual.
Secondly, we aim to help BR analysis experts and
decision-makers to navigate through the many visual
types using a series of common BR questions. An
overview of the key BR questions and the visuals pro-
posed is provided in Table T88, together with the ease of
interpretation for each visual format and possible mis-
interpretation to take in consideration.
DISCLAIMER
The processes described and conclusions drawn from
the work presented herein relate solely to the testing
of methodologies and representations for the evalua-
tion of beneﬁt and risk of medicines. This report nei-
ther replaces nor is intended to replace or comment
on any regulatory decisions made by national regula-
tory agencies or the EMA.
The views expressed in this article are the personal
views of the author(s) and may not be understood or
quoted as being made on behalf of or reﬂecting the po-
sition of the EMA or one of its committees or working
parties.
CONFLICT OF INTEREST
The PROTECT Consortium has the right of
commenting, but authors retain the right of accepting
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reviewed and approved the ﬁnal paper.
KEY POINTS
• There is not one single visual type that is consis-
tently superior to others for the communication
of BR information to various stakeholders.
• Creating visuals for communication in BR as-
sessments is too important to consider the com-
patibility Q1between a visual and its target
audience.
• We propose a number of visual types that could
be of interest when presenting information re-
lated to nine central BR questions.
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USING e-ANNOTATION TOOLS FOR ELECTRONIC PROOF CORRECTION  
 
Required software to e-Annotate PDFs: Adobe Acrobat Professional or Adobe Reader (version 7.0 or 
above). (Note that this document uses screenshots from Adobe Reader X) 
The latest version of Acrobat Reader can be downloaded for free at: http://get.adobe.com/uk/reader/ 
 
Once you have Acrobat Reader open on your computer, click on the Comment tab at the right of the toolbar:  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Replace (Ins) Tool – for replacing text. 
 
Strikes a line through text and opens up a text 
box where replacement text can be entered. 
How to use it 
 Highlight a word or sentence. 
 Click on the Replace (Ins) icon in the Annotations 
section. 
 Type the replacement text into the blue box that 
appears. 
This will open up a panel down the right side of the document. The majority of 
tools you will use for annotating your proof will be in the Annotations section, 
pictured opposite. We’ve picked out some of these tools below: 
2. Strikethrough (Del) Tool – for deleting text. 
 
Strikes a red line through text that is to be 
deleted. 
How to use it 
 Highlight a word or sentence. 
 Click on the Strikethrough (Del) icon in the 
Annotations section. 
 
 
3. Add note to text Tool – for highlighting a section 
to be changed to bold or italic. 
 
Highlights text in yellow and opens up a text 
box where comments can be entered. 
How to use it 
 Highlight the relevant section of text. 
 Click on the Add note to text icon in the 
Annotations section. 
 Type instruction on what should be changed 
regarding the text into the yellow box that 
appears. 
4. Add sticky note Tool – for making notes at 
specific points in the text. 
 
Marks a point in the proof where a comment 
needs to be highlighted. 
How to use it 
 Click on the Add sticky note icon in the 
Annotations section. 
 Click at the point in the proof where the comment 
should be inserted. 
 Type the comment into the yellow box that 
appears. 
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For further information on how to annotate proofs, click on the Help menu to reveal a list of further options: 
5. Attach File Tool – for inserting large amounts of 
text or replacement figures. 
 
Inserts an icon linking to the attached file in the 
appropriate pace in the text. 
How to use it 
 Click on the Attach File icon in the Annotations 
section. 
 Click on the proof to where you’d like the attached 
file to be linked. 
 Select the file to be attached from your computer 
or network. 
 Select the colour and type of icon that will appear 
in the proof. Click OK. 
6. Add stamp Tool – for approving a proof if no 
corrections are required. 
 
Inserts a selected stamp onto an appropriate 
place in the proof. 
How to use it 
 Click on the Add stamp icon in the Annotations 
section. 
 Select the stamp you want to use. (The Approved 
stamp is usually available directly in the menu that 
appears). 
 Click on the proof where you’d like the stamp to 
appear. (Where a proof is to be approved as it is, 
this would normally be on the first page). 
7. Drawing Markups Tools – for drawing shapes, lines and freeform 
annotations on proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be drawn on proofs and for 
comment to be made on these marks.. 
How to use it 
 Click on one of the shapes in the Drawing 
Markups section. 
 Click on the proof at the relevant point and 
draw the selected shape with the cursor. 
 To add a comment to the drawn shape, 
move the cursor over the shape until an 
arrowhead appears. 
 Double click on the shape and type any 
text in the red box that appears. 
